86 related articles for article (PubMed ID: 1878703)
1. Intensive therapy for high grade multiple myeloma (MM).
Harousseau JL; Milpied N; Jouet JP; Colombat P; Guilhot F; Laporte JP; Ifrah N; Gandhour C; Casassus P
Bone Marrow Transplant; 1991; 7 Suppl 2():28. PubMed ID: 1878703
[No Abstract] [Full Text] [Related]
2. Allogeneic bone marrow transplantation in multiple myeloma using HLA-compatible sibling donors--an EBMT Registry Study.
Gahrton G; Tura S; Ljungman P; Belanger B; Brandt L; Cavo M; Chapuis B; De Laurenzi A; de Witte T; Facon T
Bone Marrow Transplant; 1991; 7 Suppl 2():32. PubMed ID: 1878706
[No Abstract] [Full Text] [Related]
3. [Allogeneic bone marrow transplantation in multiple myeloma].
Bandini G; Rosti G; Cavo M; Albertazzi L; Rizzi S; Motta MR; Gobbi M; Tassi C; Tazzari PL; Miggiano C
Haematologica; 1989 Oct; 74(5 Suppl):463-72. PubMed ID: 2512229
[No Abstract] [Full Text] [Related]
4. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
[TBL] [Abstract][Full Text] [Related]
5. Allogenic BMT for multiple myeloma (MM). The Italian experience.
Cavo M; Tura S; Rosti G; Grimaldi M; Bandini G; Bonelli MA; Calori E; Rizzi S; Van Lint MT; Bacigalupo A
Bone Marrow Transplant; 1991; 7 Suppl 2():31. PubMed ID: 1878705
[No Abstract] [Full Text] [Related]
6. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
[TBL] [Abstract][Full Text] [Related]
7. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
Harousseau JL; Attal M; Divine M; Milpied N; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M
Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
[TBL] [Abstract][Full Text] [Related]
8. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.
Reece DE; Barnett MJ; Connors JM; Klingemann HG; O'Reilly SE; Shepherd JD; Sutherland HJ; Phillips GL
Bone Marrow Transplant; 1993 Feb; 11(2):139-46. PubMed ID: 8435663
[TBL] [Abstract][Full Text] [Related]
9. Intensive therapy for myeloma.
McElwain TJ; Meldrum M; Gore ME; Millar BC; Malpas JS
Pathol Biol (Paris); 1990 Oct; 38(8):830. PubMed ID: 2274375
[No Abstract] [Full Text] [Related]
10. [Current results of chemotherapy in multiple myeloma].
Sezaki T
Gan To Kagaku Ryoho; 1989 May; 16(5):1997-2003. PubMed ID: 2658839
[TBL] [Abstract][Full Text] [Related]
11. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
[TBL] [Abstract][Full Text] [Related]
12. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
[TBL] [Abstract][Full Text] [Related]
13. [Recent therapy for refractory myeloma].
Togawa A
Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
[TBL] [Abstract][Full Text] [Related]
14. [Intensive treatment of multiple myeloma].
Harousseau JL
Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
[TBL] [Abstract][Full Text] [Related]
15. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
Hájek R; Adam Z; Vásová I; Král Z
Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of multiple myeloma--melphalan monotherapy after bone marrow transplantation].
Hájek R; Adam Z; Krejcí M; Vásová I; Král Z; Vorlícek J
Vnitr Lek; 1996 Apr; 42(4):278-84. PubMed ID: 8693716
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
Le Blanc R; Montminy-Métivier S; Bélanger R; Busque L; Fish D; Roy DC; Kassis J; Boileau J; Lavallée R; Bélanger D; Letendre F; Hébert J; Sauvageau G; Perreault C; Roy J
Bone Marrow Transplant; 2001 Nov; 28(9):841-8. PubMed ID: 11781644
[TBL] [Abstract][Full Text] [Related]
18. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic bone marrow transplantation for multiple myeloma.
Ballester OF
Semin Oncol; 1993 Oct; 20(5 Suppl 6):67-71. PubMed ID: 8211218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
